Get access

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue

Authors


  • Disclaimer: This document contains information prepared by the American Society for Apheresis (ASFA) for the apheresis community and those who may require the use of therapeutic apheresis for their patients. Although due care has been used in the preparation of this document, ASFA makes no representation or warranty, express or implied that it is free from errors or omissions, or that it is exhaustive, and expressly disclaims all warranties, including but not limited to, warranties as to the information's quality or fitness for a particular purpose. The information contained herein is not intended to supplant the clinical judgment of qualified medical professionals. ASFA and its directors, officers, employees, members, representatives, and agents accept no liability for any loss, cost, expense, injury, or damages, whether direct, indirect, incidental, consequential, special, or other, arising from the application of the information contained in this document for patient care or any other use. The accuracy of the information contained herein is subject to changes in circumstances after the time of publication. ASFA accepts no responsibility for the accuracy and reliability of information provided by third parties.

Abstract

The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is charged with reviewing, updating and categorizating indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the “level of evidence” criteria (from the University HealthCare Consortium) utilized in prior editions given redundancy between GRADE and University HealthCare Consortium systems. The general layout and concept of a fact sheet that was utilized in the Fourth and Fifth Editions, has been largely maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. This article consists of 78 fact sheets (increased from 2010) for therapeutic indications in ASFA categories I through IV, with many diseases categorized having multiple clinical presentations/situations which are individually graded and categorized. J. Clin. Apheresis 28:145–284, 2013. © 2013 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary